Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis

Br J Haematol. 2014 Jan;164(1):146-50. doi: 10.1111/bjh.12564. Epub 2013 Sep 20.
No abstract available

Keywords: Akt; B cell receptor; chronic lymphocytic leukaemia; cytokine.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Alkylating / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Apoptosis / drug effects
  • Bendamustine Hydrochloride
  • Cytokines / biosynthesis
  • Cytokines / immunology
  • Drug Synergism
  • Heterocyclic Compounds, 3-Ring / administration & dosage
  • Heterocyclic Compounds, 3-Ring / pharmacology*
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / enzymology
  • Leukemia, Lymphocytic, Chronic, B-Cell / immunology
  • Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • Lymphocytes / drug effects
  • Lymphocytes / immunology
  • Nitrogen Mustard Compounds / administration & dosage
  • Nitrogen Mustard Compounds / pharmacology*
  • Proto-Oncogene Proteins c-akt / antagonists & inhibitors
  • Proto-Oncogene Proteins c-akt / metabolism

Substances

  • Antineoplastic Agents, Alkylating
  • Cytokines
  • Heterocyclic Compounds, 3-Ring
  • MK 2206
  • Nitrogen Mustard Compounds
  • Bendamustine Hydrochloride
  • Proto-Oncogene Proteins c-akt